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Abstract: Glioblastoma (GBM) is a disease with a poor prognosis. For decades, radiotherapy has
played a critical role in the management of GBM. The standard of care radiation prescription is 60 Gy in
30 fractions, but landmark trials have historically excluded patients older than 70 years. Currently, there
is considerable variation in the management of elderly patients with GBM. Shortened radiation treatment
(hypofractionated) regimens have been explored since conventional treatment schedules are lengthy and
many elderly patients have functional, cognitive, and social limitations. Clinical trials have demonstrated the
effectiveness of hypofractionated radiotherapy (40 Gy in 15 fractions) to treat elderly or frail patients with
GBM. Although previous studies have suggested these unique hypofractionation prescriptions effectively
treat these patients, there are many avenues for improvement in this patient population. Herein, we describe
the unique tumor biology of glioblastoma, key hypofractionated radiotherapy studies, and health-related
quality of life (HRQOL) studies for elderly patients with GBM. Hypofractionated radiation has emerged
as a shortened alternative and retrospective studies have suggested survival outcomes are similar for elderly
patients with GBM. Prospective studies comparing hypofractionation with conventional treatment regiments
are warranted. In addition to evaluating survival outcomes, HRQOL endpoints should be incorporated into
future studies.
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Introduction

significantly with age (1), with a median age of diagnosis of

Glioblastoma (GBM) is the most common primary
malignant brain tumor in adults and has a median survival
rate of 12–15 months (1). The incidence of GBM increases

65 years (2). Age is an important prognostic factor in GBM;
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elderly patients with GBM frequently have comorbidities,
unfavorable tumor biology, an increased risk of treatment
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toxicity, and may receive less aggressive treatment (3).
Currently, there is a lack of consensus regarding optimal
treatment management in the elderly population, and
elderly patients with GBM have historically been excluded
from landmark clinical trials (4,5). Randomized trials that
included elderly patients have demonstrated the survival
benefit of radiation therapy (RT) over supportive care (6).
Hypofractionated RT has emerged as a common alternative,
and some studies have shown short-course regimens may
result in similar or improved outcomes for elderly patients
with GBM (7,8). Herein, we discuss the current standard
of care for GBM, differences in tumor biology within the
elderly patient population, studies evaluating the role of
hypofractionation in elderly patients with GBM, and how
hypofractionation impacts health-related quality of life
(HRQOL).
Glioblastoma management
Surgery
Maximal safe resection is generally recommended for
GBM patients (9). Randomized trials have reported
subtotal or gross total resection (GTR) versus biopsy alone
increases overall survival (OS) (10). GTR also improves
survival outcomes in the elderly patient population (11). A
randomized trial including elderly patients compared surgical
resection to biopsy alone and found surgical resection
resulted in improved OS (171 vs. 85 days) (12). When
surgical resection is not possible, stereotactic or open biopsy
can obtain a histologic diagnosis to assist with molecular
testing. With recurrent GBM, salvage surgery is sometimes
considered in patients with good performance status if
>6 months has passed since initial surgical resection (13).
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Clinical Trials Group (NCIC CTG) (2). In 2010, Chen
et al. conducted a phase I trial determining the maximal
tolerated RT dose intensification with temozolomide
(TMZ) in patients with newly diagnosed GBM (17). This
study reported 60 Gy in 6 Gy fractions within 2 weeks with
concomitant and adjuvant TMZ had acceptable tolerance
in patients with a T1-weighted enhancing tumor less than
6 cm. Multiple studies evaluating dose-escalation have not
shown a survival advantage, although a recent meta-analysis
suggests a potential benefit in certain populations (18-20).
Although studies have shown elderly patients have
improved survival with RT versus supportive care alone
without reducing QOL or cognition (6), shorter-course
radiation alternatives were explored in hopes of decreasing
treatment burden while still preserving survival outcomes.
In a randomized study of patients ≥60 years, there was no
significant difference in OS or QOL in the standard arm
(60 Gy in 30 fractions) versus the hypofractionated arm
(40 Gy in 15 fractions) (8). Subsequently, Roa et al.
compared two RT regimens (short-courses 25 Gy in
5 fractions vs. 40 Gy in 15 fractions) (21). The authors
found there was no significant difference in OS, progression
free survival (PFS), and QOL between the two schedules,
suggesting the shortened 1-week regimen may be an
appropriate option for selected elderly patients with GBM.
Systemic therapy

RT plays a key role in the management of GBM to
improve local control and OS. Multiple phase III trials
have demonstrated the benefit of adjuvant RT for patients
with GBM (7,14-16). A prior Brain Tumor Study Group
study showed a significant dose-response relationship that
revealed an increase in OS when incrementally increasing
the radiation dose from 45 to 60 Gy (15). Currently, the
treatment standard of 60 Gy in 30 fractions over six weeks
is based on a phase III trial conducted by the European
Organization for Research and Treatment of Cancer
(EORTC) and the National Cancer Institute of Canada

TMZ is an alkylating agent that has ushered in a new
standard of care for patients with newly diagnosed
GBM. In 2005, a phase III study by the EORTC and the
National Cancer Institute of Canada Clinical Trials Group
(NCIC) found the addition of TMZ to RT (60 Gy in
30 fractions) resulted in a significantly improved median
OS compared to RT alone (14.6 vs. 12.1 months) (2). The
survival advantage was sustained throughout five years of
follow-up, and patients with MGMT promoter methylation
were more likely to benefit from the chemotherapy (22).
These findings changed the standard of care, and modern
hypofractionation studies also include TMZ (23).
The Nordic trial explored a different hypofractionated
schedule of 34 Gy in 10 fractions (7). In their study,
there were three treatment arms: standard RT (60 Gy
in 30 fractions), hypofractionated radiation of 34 Gy in
10 fractions, or TMZ alone (administered days 1 to
5 every 28 days for up to six cycles). For patients older
than 70 years, survival was better with hypofractionated
RT compared to standard RT. Notably, patients who
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received the protracted radiotherapy regimen of 60 Gy in
30 fractions in both the Roa and Nordic studies had a high
rate of radiation discontinuation prior to completing the
full radiation prescription (7,21). More recently, Perry et al.
conducted a phase III trial evaluating the addition of TMZ
to short-course RT regimens (23). In this study, TMZ
added a survival benefit compared to RT alone (9.3 vs. 7.6
months). A more detailed discussion of hypofractionation
in the elderly population will be outlined in later sections.
Wick et al. published results from NOA-08 suggesting
patients >65 years with specific biomarkers may have
favorable long-term outcomes with TMZ monotherapy
(24,25). In the study, receptor tyrosine kinase I (RTK I) and
mesenchymal subgroups were not strong prognostic factors,
but patients with the IDH-WT RTK II methylation
subclass demonstrated the largest benefit by multivariate
analysis.
A phase II trial evaluated the addition of bevacizumab,
a monoclonal antibody to VEGF (vascular endothelial
growth factor), to hypofractionated RT and TMZ to reduce
radionecrosis and improve disease control (26). Although the
median OS was 16.3 months, bevacizumab failed to decrease
the high rate of radiation necrosis. Another phase II study
of patients with recurrent GBM treated with RT (30 Gy
in 5 fractions) plus bevacizumab reported no radionecrosis
with a median survival of 12.5 months (27). Youland et al.
conducted a retrospective analysis of patients with recurrent
high-grade gliomas treated with reirradiation; in their study,
the authors noted radionecrosis occurred in four patients,
but no radionecrosis was observed in patients receiving
concurrent bevacizumab (0% vs. 19%, P=0.03) (28).
RTOG 0825 sought to determine if the addition of
bevacizumab to the standard of care improved OS or PFS
in newly diagnosed GBM (29). The authors determined
bevacizumab did not improve OS and did improve PFS,
but did not reach significance. Bevacizumab has also been
used concurrently with hypofractionated reirradiation in
the NRG/RTOG 1205 phase II trial (30). Although the
study confirmed the safety of reirradiation, bevacizumab
plus hypofractionated RT did not demonstrate improved
median OS. The phase II ARTE trial randomized patients
≥65 years to hypofractionated RT (40 Gy in 15 fractions)
with or without bevacizumab (31). Although the study results
did not suggest bevacizumab improves survival outcomes,
molecular biomarkers may be a useful tool for identifying
patients that may benefit from
Investigators are now interested in combining
hypofractionated RT with agents that may potentially led to
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radiosensitization or anti-tumor effects (32). A phase I study
evaluated gefitinib, a tyrosine kinase inhibitor, in patients
with recurrent GBM (33). Fractionated SRS (36 Gy in three
fractions) with gefitinib (daily dose of 250 mg) was well
tolerated.
Tumor-treating fields (TTFields)
TTFields is a non-invasive treatment approach involving
alternating electrical fields (34). Researchers propose
TTFields are able to inhibit cancer cell proliferation by
interfering with microtubule polymerization (35). Stupp et al.
demonstrated the addition of tumor-treating fields to RT and
TMZ resulted in a statistically significant improvement in
PFS and OS (36). In their final analysis, the authors reported
median OS was 20.9 months in the radiation, TMZ, and
tumor-treating field group and 16.0 months in the radiation
and TMZ-alone group. In the subgroup analysis, patients
≥65 years maintained the survival benefit with the addition of
tumor-treating fields (17.4 vs. 13.7 months).
Pulsed radiotherapy
Pulsed RT is a novel low-dose rate therapy strategy
that divides 2 Gy fractions into ten 0.2 Gy pulses. This
treatment modality has demonstrated efficacy in GBM
preclinical studies (37,38) and may result in superior
normal-tissue sparing compared to stereotactic RT. In 2021,
the first prospective trial results investigating pulsed RT in
patients with newly diagnosed GBM found median OS was
longer (20.9 months) compared to historical controls with
no decline in QOL or neurocognitive function (39).
Tumor biology differences in elderly patients
Research suggests elderly patients with GBM may have
less favorable molecular signatures compared with younger
patients (40). Bozdag et al. (41) analyzed patients from The
Cancer Genome Atlas and found elderly patients (≥70 years)
with GBM exhibited pro-angiogenic phenotypes compared
to younger patients (≤40 years) using computational
analyses of high-throughput genomic data. Furthermore,
another study suggested that certain genetic markers have
variable effects on survival based on age; in one study,
genetic alterations in TP53 and CDKN2A/p16 were
prognostically unfavorable in older patients, but favorable
in younger patients (42). A study by Nghiemphu et al. found
older patients with GBM (≥55 years) had a 1.4-fold higher
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expression of vascular endothelial growth factor (VEGF)-A
than younger patients (43). One phase II trial has found
the addition of bevacizumab to TMZ in a cohort of elderly
patients ≥70 years had an acceptable tolerance level (44).
Methylation status of MGMT has also been found to be
an important prognostic factor. The Nordic trial reported
patients ≥60 years treated with TMZ with MGMT
promoter methylation had significantly longer survival than
those without methylation (9.7 vs. 6.8 months), similar to
what was reported in other trials (7). As researchers uncover
additional molecular factors unique to elderly patients with
GBM, there is the hope that additional targeted treatments
will be developed and implemented.
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There is significant variation in the elderly GBM
management and a pressing need to find an optimal
treatment approach for the elderly population (48). Critical
trials that were used to establish the standard of care for
patients with newly diagnosed GBM set the upper age
limit to 70 years (2,22). This age cut-off was controversial
considering the median age of newly diagnosed GBM is
65 years according to data from various countries (49-51).
Furthermore, studies found patient outcomes decline with
age (52), suggesting the established treatment regimen
may not be suitable for the elderly population. Elderly
patients frequently have various functional, cognitive,
and social limitations (53); tools have been developed to
group elderly cancer patients based on functional status,
comorbidities, cognition, nutritional status, psychological

state, and social support [e.g., comprehensive geriatric
assessment (CGA)] (54). Varying hypofractionation schemes
have been reported in the literature that range from
“moderate” (3 Gy) to “extreme” (5–8 Gy) for the elderly
or frail patient population with poor prognosis (55-60).
Researchers have surmised hypofractionated RT may limit
tumor repopulation (61), increase cell kill (62), and improve
local control in certain radioresistant tumors (63) while
decreasing overall treatment time.
Over the past decade, numerous disease sites (e.g., breast,
prostate, rectum) have transitioned to hypofractionated
regimens; a paradigm shift that was, in part, a result of
technological advances in RT that have allowed the use of
high dose-per-fraction (64). Many trials have determined
short-course RT outcomes are non-inferior (65-68) and
some studies have found short-course schedules were
associated with decreased treatment failure (69). The
current standard of care for GBM is 60 Gy in 30 fractions
for patients <70 years and a hypofractionated regimen (e.g.,
40 Gy in 15 fractions) as an acceptable, more convenient
alternative for elderly or frail patients (8). To date, there
have not been large phase III clinical trials comparing
the standard of care radiation (60 Gy in 30 fractions) to
hypofractionated RT (40 Gy in 15 fractions). Nonetheless,
studies involving elderly patients with GBM have been
conducted, and key studies are highlighted below.
In 2004, the EORTC/NCIC phase III trial by Stupp et al.
demonstrated improved median and 2-year survival for
patients with GBM treated with RT plus TMZ (2). A 5-year
analysis found the benefits of TMZ with RT were sustained
throughout follow-up and MGMT status was the strongest
prognostic factor (22). Additionally, the updated analysis
demonstrated all prognostic subgroups had improved OS
with the addition of TMZ. Notably, a survival benefit was
reported in patients 60–70 years (22).
Given the poor survival outcomes of elderly patients
with GBM, investigators were uncertain if the treatment
burden associated with 6 weeks of RT provided significant
benefit compared to shorter-course regimens. Roa et al.
conducted a prospective study comparing standard RT
(60 Gy in 30 fractions, n=51) and a shorter-course (40 Gy
in 15 fractions, n=49) in patients ≥60 years with GBM (8).
OS were similar between the two groups (5.1 months for
standard vs. 5.6 months for hypofractionated). However, this
trial was designed as a superiority trial and was not powered
to determine non-inferiority of the hypofractionated arm.
Of note, a larger proportion of patients (26% in the standard
arm vs. 10% in the short course arm) did not complete

© Chinese Clinical Oncology. All rights reserved.

Chin Clin Oncol 2022;11(5):38 | https://dx.doi.org/10.21037/cco-22-76

Modern day hypofractionation
The history of radiation fractionation has evolved
significantly over nearly a century. As early as the 1930s,
pioneers in the field reported splitting the total radiation
dose into smaller fractions resulted in favorable clinical
outcomes compared to a single dose (45). For decades, a
fraction size of 2 Gy was considered to be the standard
while increases in fraction size (≥3 Gy) were coined
“hypofractionation” (46). In recent decades, technological
advances (e.g., three-dimensional treatment planning,
intensity modulated radiation therapy, stereotactic
radiotherapy) have led to a paradigm shift, allowing
providers to deliver high-doses to the tumor/target volume
while sparing normal tissue (47).
Hypofractionated radiotherapy in the elderly
population
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radiation treatment.
In 2012, Malmström et al. published results from
the Nordic phase III trial comparing TMZ (n=93),
hypofractionated RT (34 Gy in 10 fractions over 2 weeks,
n=98), and standard RT (60 Gy in 30 fractions over
6 weeks, n=100) for patients ≥60 years (7). Median OS was
significantly longer with TMZ compared to standard RT
(8.3 vs. 6.0 months), but OS was similar for patients who
received TMZ or hypofractionated RT (8.4 vs. 7.4 months).
For patients older than 70 years, TMZ and hypofractionated
RT resulted in improved survival compared to standard RT.
The authors also reported patients with MGMT promoter
methylation had significantly longer survival (9.7 vs.
6.8 months). Again, a greater proportion of patients
receiving standard treatment did not finish their prescribed
radiation course (28% vs. 5% in the hypofractionated arm).
In a phase III study, Roa et al. explored alternative RT
regimens for elderly and/or frail patients: either a shortercourse (25 Gy in 5 fractions, n=48) or the common
hypofractionated regimen (40 Gy in 15 fractions, n=50) (21).
The authors reported the short-course was non-inferior;
median OS was greater in the short-course arm (7.9 vs.
6.4 months) and median PFS rates were equivalent in both
arms (4.2 months). However, 56% of the patients on this
study had Karnofsky Performance Status (KPS) <70%, so it
may be more applicable for selected frail and elderly patients.
In 2017, Perry et al. conducted a randomized trial
evaluating the benefit of adding TMZ to shorter course
RT (40 Gy in 15 fractions) (23). The trial included patients
≥65 years who were randomized to RT alone or RT plus
concomitant and adjuvant TMZ. The addition of TMZ
resulted in longer median OS (9.3 vs. 7.6 months) and
median PFS (5.3 vs. 3.9 months). Subgroup analysis revealed
patients with methylated MGMT status had a greater TMZ
benefit (13.5 vs. 7.7 months, P<0.001), but patients with
unmethylated MGMT status also experienced a survival
benefit that approached but did not reach significance (10.0
vs. 7.9 months, P=0.06).
Today, a standard RT prescription for elderly patients
with GBM is 40 Gy in 15 fractions. However, the BED for
40 Gy in 15 fractions is lower than the BED for 60 Gy in
30 fractions. Previous studies have shown dose escalation
from 45 to 60 Gy has significant survival improvement at
each interval, suggesting that elderly patients receiving
40 Gy in 15 fractions may be underdosed (15). An analysis
by Perlow et al. evaluated outcomes of elderly GBM patients
(≥65 years) that received either 52.5 Gy in 15 fractions or
40 Gy in 15 fractions (70). The authors found OS was

greater in the 52.5 Gy group compared to the 40 Gy group
(14.1 vs. 7.9 months); there were no significant differences
between treatment groups. Furthermore, there was not a
significant difference in toxicity between the two treatment
groups and no grade IV or V toxicities. These findings
suggest RT de-escalation in the elderly or frail population
may negatively impact survival outcomes.
A subsequent study by Perlow et al. pooled elderly and/
or frail patients with GBM from 3 phase I/II studies and a
prospective registry study (71). Patients ≥65 years or with
a KPS <70 treated with accelerated hypofractionated RT
(52.5 Gy in 15 fractions) were included in the analysis. The
median age for this study was 73 years and patients had a
median OS and PFS or 10.3 and 6.9 months, respectively.
Grade III toxicity was only observed in 2 patients (3.2%)
and there were no grade IV or V toxicity. Compared to
prior studies (7,21,23,72), this hypofractionated isoeffective
RT regimen had superior OS (10.3 vs. 6.4–9.3 months)
without a notable increase in toxicity.
There have been other hypofractionated accelerated
RT treatment schedules (60 Gy in 20 fractions) that have
demonstrated comparable survival outcomes to conventional
RT, but excluded elderly patients (73,74). Elderly patients
with good KPS scores may be appropriate candidates for
this treatment regimen, but retrospective and prospective
evaluation is needed.
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HRQOL
HRQOL is increasingly being recognized as an important
end point, particularly for patients with aggressive
cancers (75,76). GBM treatment and disease-related sideeffects may include cognitive dysfunction, fatigue, and
personality changes that can affect the social interactions
and the ability to perform activities of daily living (77). As
hypofractionation survival outcomes are being assessed
in elderly patients with GBM, monitoring the effects to
HRQOL is of equal importance.
Several studies have found a hypofractionated regimen
does not lead to a significant decline in HRQOL within the
elderly patient population. Minniti et al. reported elderly
patients that received 40 Gy in 15 fractions had stable
or improved HRQOL (78). Reddy et al. similarly found
hypofractionation (60 Gy in 10 fractions) was associated
with stable HRQOL as well as an improvement in insomnia,
future uncertainty, motor dysfunction, and drowsiness (79).
Radiation necrosis is a potential side effect of
hypofractionated RT (80), and symptomatic radiation
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necrosis frequently leads to a decline in HRQOL (81).
Bevacizumab has been explored as a potential agent for
reducing rates of symptomatic necrosis and brain edema
via decreasing vascular permeability (27). In a phase II trial
for newly diagnosed GBM, Omuro et al. demonstrated
an aggressive RT schedule (36 Gy in 6 fractions) with
concomitant and adjuvant bevacizumab was safe and
convenient for patients (82). A subsequent phase I/II trial
by Pollom et al. assessed longitudinal HRQOL in patients
treated with dose escalated five-fraction SRS (25–40 Gy in
5 fractions) and found no significant changes in HRQOL
compared to historical controls (83). In this trial, patients
who experienced symptomatic adverse radiation effects
were treated with bevacizumab. Although 27% of patients
experienced adverse radiation-related effects with doseescalation, there was not a significant decline in HRQOL.
These findings suggest dose escalation may be clinically
favorable.
Perspective
Defining “elderly”
Currently, the literature lacks a clear definition of what is
defined as “elderly”, where some studies consider patients
that are 60 years (8) while others choose ≥65 years (23) as
the cut-off age. A propensity score matched analysis found
outcomes were similar in patients aged 65–69 compared
to older patients ≥70 years (84). This finding suggests
hypofractionated regimens should also be considered in this
group of younger elderly patients with GBM.
The need for prospective studies
Numerous studies have evaluated hypofractionated RT
in elderly patients with GBM, but many of these studies
are retrospective. Furthermore, there is significant
heterogeneity in the hypofractionation schemes (e.g.,
number of fractions, total dose), making it difficult to
interpret available data. To date, there is a lack of prospective
trials comparing hypofractionation with conventional RT
in the elderly population. Hypofractionation appears to be
a safe, well-tolerated alternative for elderly or frail patients
with GBM, and there is a need for adequately powered
prospective studies comparing hypofractionation and
conventional fractionated RT survival outcomes. A phase
III trial (NCT05439278, not yet recruiting) is planning to
compare outcomes of patients ≥70 years receiving either

© Chinese Clinical Oncology. All rights reserved.

Matsui et al. Radiotherapy for elderly patients with GBM

conventional RT (60 Gy in 6 weeks) or hypofractionated
RT (40 Gy in 3 weeks). Lastly, there is a need for effective
treatment options following GBM recurrence. One such
study is NCT05393258 (recruiting) that is evaluating
temporally modulated pulsed RT delivered in multiple
small doses.
Conclusions
Glioblastoma is one of the most aggressive cancer types
and is associated with a poor prognosis, particularly in the
elderly population. Currently, there is an ongoing debate
regarding optimal treatment management in this specific
patient population. Less aggressive interventions may be
employed since elderly patients commonly have functional,
cognitive, and social limitations. Historically, RT has played
a critical role in the management of GBM, but conventional
treatment schedules are typically lengthy and may lead to
early treatment discontinuation (7,21). Hypofractionated
RT has emerged as a shortened alternative and retrospective
studies have suggested survival outcomes are similar for
elderly patients with GBM. Prospective studies comparing
hypofractionation with conventional treatment regimens
are warranted. In addition to evaluating survival outcomes,
HRQOL end points should be incorporated into future
studies.
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